CBER 2025 Orphan Approvals (new BLAs)
CBER 2025 Orphan Approvals (new BLAs)
Related Articles
It’s Almost Flu Season. Should You Still Get a Shot, and Will Insurance Cover It?
For parents of school-aged children, the fall to-do list can seem ever-growing. Buy school supplies. Fill out endless school forms. Block off parent-teacher nights. Do…
An Arm and a Leg: The Prescription Drug Playbook, Part II
In response to the high price of prescription drugs, “An Arm and a Leg” asked listeners to share their strategies for getting the medicine they…
KFF Health News’ ‘What the Health?’: American Health Gets a Pink Slip
The Host Julie Rovner KFF Health News @jrovner Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health…
Approved Blood Products
Products that are regulated as Biologics License Applications (BLAs), New Drug Applications (NDAS), Premarket Approvals (PMAs), and 510(k)s.
CBER Rare Disease Program
Description of CBER’s Rare Disease Program, including a description of the program, selected activities, examples of collaborations internal and external to CBER, and frequently asked questions.
